ArticleThe oncologist2026

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.

Haishuang Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.